Improving smoking cessation in the African American community with extended bupropion treatment
Improving Smoking Abstinence Outcomes in the African American Community Through Extended Treatment
PHASE3 · University of Kansas Medical Center · NCT05732272
This study is testing if longer treatment with bupropion can help African American daily smokers quit smoking better than the usual shorter treatment, along with personalized counseling.
Quick facts
| Phase | PHASE3 |
|---|---|
| Study type | Interventional |
| Enrollment | 500 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | University of Kansas Medical Center (other) |
| Locations | 1 site (Kansas City, Missouri) |
| Trial ID | NCT05732272 on ClinicalTrials.gov |
What this trial studies
This study evaluates the effectiveness of extended bupropion treatment for smoking cessation among African American daily smokers. Participants will be randomly assigned to receive either 6 months of bupropion or the standard 7 weeks of treatment, along with culturally-relevant smoking cessation counseling. The study aims to enhance abstinence rates by providing support tailored to the needs of the participants. A total of 500 individuals will be enrolled and followed for 12 months to assess outcomes.
Who should consider this trial
Good fit: Ideal candidates are African American adults over 18 who are daily smokers and interested in quitting.
Not a fit: Patients with a history of substance abuse, certain medical conditions, or contraindications to bupropion may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could significantly improve smoking cessation rates in the African American community.
How similar studies have performed: Other studies have shown promising results with extended bupropion treatment for smoking cessation, suggesting this approach may be effective.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * African American * age \>18 years * interested in quitting * smoked \>1 cpd for \>1 years * smoked on \>25 days in the past month * willing to take 6 months of study medication and complete all visits * have a home address and functioning telephone number Exclusion Criteria: * Consistent with contraindications for bupropion: * use of psychoactive medications * history of alcohol or substance abuse within the past year * binge drinking (\>5 drinks on one occasion) \>2 times in the past month * history of seizures or head trauma; history of bulimia or anorexia nervosa * pregnant (as measured by over the counter pregnancy test kit for women of child-bearing age only) or contemplating pregnancy; breast feeding * myocardial infarction in the past 2 months * reported use of opiates, cocaine, or stimulants * unstable diabetes * bupropion is a known inhibitor of the liver enzyme CYP2D6, so those taking drugs known to be higher metabolized by this enzyme (e.g., metoprolol, tamoxifen) will be excluded. * use of stop smoking medications (bupropion, varenicline, nicotine replacement, fluoxetine, clonidine, buspirone, or doxepin) in the past 30 days * planning to move from the Kansas City area in the next year * other smoker in household enrolled in the study.
Where this trial is running
Kansas City, Missouri
- University of Kansas Medical Center — Kansas City, Missouri, United States (RECRUITING)
Study contacts
- Principal investigator: Lisa Sanderson Cox, PhD — University of Kanas Medical Center
- Study coordinator: Tricia Snow, MPH
- Email: psnow@kumc.edu
- Phone: 816-398-8960
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Smoking Cessation